Company Overview
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
Recent News
Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
Stock Overview
Symbol
AMBS
Exchange
OTCPink
Shares OS
68,272,000
Market Cap
$0
Last Price
$
52-Week Range
$ - $
Fiscal Year End
December 31
Last Trade Time
Investor Relations
American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com